egorical regression model. First the estimation procedure was validated through estimation of the MAUF for the EQ-5D attributes based on the exiting Spanish tariff scores for the instrument. Secondly the MAUF for the SF-6D attributes was estimated regressed on the EQ-5D tariff scores. Weights were rescaled to yield scores ranging from worse possible state (0) to full health (1). RESULTS: All estimated attribute weights were significant and goodness of fit was reasonable ($R^2 = 0.799$). Spanish utility values for the same health states are significantly different from those used in the UK: 0.7458 (0.208) vs. 0.7090 (0.143), $p < 0.001$. The shape of utility scores obtained with the Spanish MAUF exhibits a cubic pattern as compared to the British. Utilities obtained by the Spanish MAUF are higher for benign health states while severe states attain lower utilities. CONCLUSION: The proposed method allows for a valid and reliable estimation of a MAUF based on kown utilities of a concurrent instrument, avoiding the need of incomplete designs to collect preferences. Evident differences between culture specific scoring systems encourage adapting instruments to the target culture in order to obtain valid measures. Spanish weights for SF-6D are now available to be used with existing or new SF-36v1 databases.

**PGI28**

**IMPACT OF CERTOLIZUMAB PEGOL ON QUALITY-ADJUSTED LIFE-YEARS IN TWO INDUCTION AND MAINTENANCE TRIALS IN PATIENTS WITH ACTIVE CROHN’S DISEASE**

Tan SC1, Gerlier LC2, Brown M1

1UCB, Slough, Berkshire, UK, 2Keyrus Biopharma, Levallois-Perret, France

OBJECTIVES: The efficacy and safety of certolizumab pegol (CZP), a PEGylated anti-TNF, in patients with active Crohn’s disease (CD) have been demonstrated in two 26-week induction and maintenance trials, PRECiSE 1 (Sandborn et al., 2005) and PRECiSE 2 (Schreiber et al., 2005). This analysis evaluated the effect of CZP versus placebo on quality-adjusted life-years (QALYs) for each subject in these trials. METHODS: In PRECiSE 1, patients with active CD received double-blind CZP 400 mg (n = 331) or placebo (n = 328) every 4 weeks after induction. PRECiSE 2 began with an open-label induction period (CZP 400 mg at Weeks 0, 2 and 4). Patients who demonstrated a clinical response at Week 6 were randomised to receive CZP 400 mg (n = 215) or placebo (n = 210) every 4 weeks from Weeks 8 to 24. The EQ-SD was administered at each visit and converted into utility scores using an established algorithm (Dolan et al., 1995). An estimate of QALYs was made for each patient from the area under the utility curve during the randomisation period of each trial. Mean QALYs and standard deviation (SD) were calculated by treatment group and compared using a Wilcoxon rank sum test. RESULTS: Over the 26-week PRECiSE 1 trial, the mean (SD) QALYs were 0.5456 (0.2993) for CZP and 0.4797 (0.3121) for placebo. Similarly, between Weeks 6 and 26 of PRECiSE 2, the mean (SD) QALYs were 0.4976 (0.2047) in the CZP group versus 0.4286 (0.2171) in the three injection followed by placebo group. A statistically significant gain in QALYs with CZP was observed in both trials: PRECiSE 1 0.0659 ($p = 0.001$); PRECiSE 2 0.0690 ($p = 0.015$). CONCLUSION: CZP improved both quality and quantity of remission and response period, as measured by QALYs, significantly more than placebo among patients with CD in two 26-week maintenance trials.

**HEALTH CARE USE & POLICY STUDIES**

**PHPI**

**ECONOMIC ANALYSIS OF THE BAVARIAN BLOOD AND PLASMA MARKET: LESSONS FOR THE FUTURE**

Rottenkolber D1, Berger K1, Petermann A2, Weinauer F1, Schramm W1

1University Hospital of Munich, Munich, Germany, 2Blutspendezien des Bayerischen Roten Kreuzes gGmbH, Munich, Germany

OBJECTIVES: To estimate demand and supply of blood products in Bavaria, as due to intransparency on prices and trade volumes reliable data are missing and to support optimal planning of blood supply and usage in Bavaria within the next two decades. METHODS: Data were collected through desk-top researches on demographics (e.g. Federal Statistical Office Germany, Bavarian State Office for Statistics and Data Processing), blood usage and donation behaviour in Germany (Robert Koch Institute, Paul-Ehrlich-Institute, Bavarian Red Cross) and